Effects of risperidone on auditory event-related potentials in schizophrenia

International Journal of Neuropsychopharmacology

Volumn 2, Issue 4, 1999, Pages 299-304

  Umbricht, Daniel ^a,b   Javitt, Daniel ^b,c   Novak, Gerald ^b   Bates, John ^b   Pollack, Simcha ^b,d   Lieberman, Jeffrey ^e   Kane, John ^b  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d ST JOHN'S UNIVERSITY   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Atypical antipsychotics; Cognitive deficits; Event related potentials (ERPs); Risperidone; Schizophrenia; Treatment

Indexed keywords

EID: 0001325240     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145799001595     Document Type: Article

References (29)

1. American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders, III (3rd rev. edn). Washington, DC: American Psychiatric Association.
2. Blackwood DH, Whalley LJ, Christie JE, Blackburn IM, St Clair DM, McInnes A (1987). Changes in auditory P3 event-related potential in schizophrenia and depression. British Journal of Psychiatry 150, 154-160.
3. Cancro R, Sutton S, Kerr J, Sugerman AA (1971). Reaction time and prognosis in acute schizophrenia. Journal of Nervous and Mental Disease 153, 351-359.
4. Catts SV (1995). Brain potential evidence for an auditory sensory memory deficit in schizophrenia. American Journal of Psychiatry 152, 213-219.
5. Ford JM, White PM, Csemansky JG, Faustman WO, Roth WT, Pfefferbaum A (1994). ERPs in schizophrenia: effects of antipsychotic medication. Biological Psychiatry 36, 153-170.
6. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, Schulz SC, Weinberger DR (1993). The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. British Journal of Psychiatry 162, 43-48.
7. Green MF (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry 153, 321-330.
8. Green MF, Marshall BD Jr., Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J (1997). Does risperidone improve verbal working memory in treatment-resistant schizophrenia? American Journal of Psychiatry 154, 799-804.
9. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY (1993). Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry 34, 702-712.
10. Hoff AL, Faustman WO, Wieneke M, Espinoza S, Costa M, Wolkowitz O, Csemansky JG (1996). The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology 15, 361-369.
11. Javitt DC, Doneshka P, Grochowski S, Ritter, W (1995). Impaired mismatch negativity generation reflects widespread dysfunction of working memory in schizophrenia. Archives of General Psychiatry 52, 550-558.
12. Johnson R (1986). For distinguished early career contribution to psychophysiology: award address, 1985. Psychophysiology 23, 367-384.
13. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-271.
14. Kern RS, Green MF, Marshall BD Jr., Wirshing WC, Wirshing D, McGurk S, Marder SR, Mintz J (1998). Risperidone vs. haloperidol on reaction time, manual dexterity and motor learning in treatment-resistant schizophrenia patients. Biological Psychiatry 44, 726-732.
15. McGurk SR, Meltzer HY (1997). The effects of atypical antipsychotic drugs on cognitive functioning in schizophrenia. Schizophrenia Research 29, 160.
16. Näätänen R (1990). The role of attention in auditory information processing as revealed by event-related potentials and other brain measures of cognitive function. Behavioral and Brain Sciences 13, 201-208.
17. Novak GP, Ritter W, Vaughan HG, Wiznitzer ML (1990). Differentiation of negative event-related potentials in an auditory discrimination task. Electroencephalography and Clinical Neurophysiology 75, 255-275.
18. O'Donnell BF, Shenton ME, McCarley RW, Faux SF, Smith RS, Salisbury DF, Nestor PG, Pollak SD, Kikinis R, Jolesz, FA (1993). The auditory N2 component in schizophrenia: relationship to MRI temporal lobe gray matter and to other ERP abnormalities. Biological Psychiatry 34, 26-40.
19. Pfefferbaum A, Ford JM, White PM, Roth WT (1989). P3 in schizophrenia is affected by stimulus modality, response requirements, medication status, and negative symptoms. Archives of General Psychiatry 46, 1035-1044.
20. Polich J, Kok A (1995). Cognitive and biological determinants of P300: an integrative review. Biological Psychology 41, 103-146.
21. Pritchard WS (1986). Cognitive event-related potential correlates of schizophrenia. Psychological Bulletin 100, 43-66.
22. Ritter W, Simson R, Vaughan HG Jr. (1983). Event-related potential correlates of two stages of information processing in physical and semantic discrimination tasks. Psychophysiology 20, 168-179.
23. Ritter W, Simson R, Vaughan HG Jr., Friedman, D (1979). A brain event related to the making of a sensory discrimination. Science 203, 1358-1361.
24. Schall U, Catts SV, Chaturvedi S, Redenbach J, Karayanidis F, Ward PB (1995). The effect of clozapine therapy on psychometric and event-related potential (ERP) measures on cognitive dysfunction in schizophrenia. Schizophrenia Research 15, 164.
25. Stip E, Lussier I (1996). The effect of risperidone on cognition in patients with schizophrenia. Canadian Journal of Psychiatry/Revue Canadienne de Psychiatrie 41 (Suppl. 2), S35-S40.
26. Umbricht D, Javitt DC, Novak GP, Bates JA, Pollack S, Lieberman J, Kane J (1998). Effects of clozapine on auditory event-related potentials in schizophrenia. Biological Psychiatry 44, 716-725.
27. Woemer MG, Manuzza S, Kane JM (1988). Anchoring the Brief Psychiatric Rating Scale; an aid to improve reliability. Psychopharmacology Bulletin 24, 112-117.
28. Zahn TP, Carpenter WT (1978). Effects of short-term outcome and clinical improvement on reaction time in acute schizophrenia. Journal of Psychiatric Research 14, 59-68.
29. Zahn TP, Pickar D, Haier RJ (1994). Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia. Schizophrenia Research 13, 133-144.